Last reviewed · How we verify
Antiplatelet or Anticoagulant Therapy
Inhibits platelet aggregation
Inhibits platelet aggregation Used for Atrial fibrillation, Acute coronary syndrome.
At a glance
| Generic name | Antiplatelet or Anticoagulant Therapy |
|---|---|
| Sponsor | Syntrillo, Inc |
| Drug class | Antiplatelet |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
Antiplatelet agents work by inhibiting the activation and aggregation of platelets, which play a key role in the formation of blood clots.
Approved indications
- Atrial fibrillation
- Acute coronary syndrome
Common side effects
- Gastrointestinal bleeding
- Thrombocytopenia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) (PHASE4)
- Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion (ETICA) (NA)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiplatelet or Anticoagulant Therapy CI brief — competitive landscape report
- Antiplatelet or Anticoagulant Therapy updates RSS · CI watch RSS
- Syntrillo, Inc portfolio CI